1.80 score from hupso.pl for:
one-ventures.com.au



HTML Content


Title oneventures - investment and venture capital

Length: 49, Words: 6
Description pusty

Length: 0, Words: 0
Keywords pusty
Robots index,follow
Charset UTF-8
Og Meta - Title pusty
Og Meta - Description pusty
Og Meta - Site name pusty
Tytuł powinien zawierać pomiędzy 10 a 70 znaków (ze spacjami), a mniej niż 12 słów w długości.
Meta opis powinien zawierać pomiędzy 50 a 160 znaków (łącznie ze spacjami), a mniej niż 24 słów w długości.
Kodowanie znaków powinny być określone , UTF-8 jest chyba najlepszy zestaw znaków, aby przejść z powodu UTF-8 jest bardziej międzynarodowy kodowaniem.
Otwarte obiekty wykresu powinny być obecne w stronie internetowej (więcej informacji na temat protokołu OpenGraph: http://ogp.me/)

SEO Content

Words/Characters 1841
Text/HTML 18.05 %
Headings H1 0
H2 13
H3 17
H4 4
H5 0
H6 0
H1
H2
about oneventures
the oneventures team
funds
investment portfolio
awards and accolades
latest news
oneventures awarded biomedical translation $170m funding
oneventures awarded biomedical translation $170m funding
data published in cancer medicine demostrate clinical genomics' blood test for colorectal cancer recurrence is two-fold more sensitive than cea test
clinical genomics strenghtens it's leadership team with multiple key appointments
media release - oneventures appoints dr graeme wald to life sciences investment team
dror ben-naim puts digital power in professor's hands
contact us
H3
connect with us
board of directors
innovation fund (fund i)
innovation and growth fund (fund ii)
information for stakeholders interested in the significant investment visa (siv) programme
oneventures innovation fund (fund i)
oneventures innovation and growth fund (fund ii)
other investments
smart sparrow
vaxxas
incoming media
incoming media
smart sparrow
vaxxas
for entrepreneurs
for investors
general enquiries
H4 see all awards
see all news
sydney
brisbane
H5
H6
strong
dr michelle deaker
dr paul kelly
anne-marie birkill
graeme wald
dr amir zalcenstein
james mcgrath
helen liu
jelly jakob
jen ball
walter lewin
simon moore
roger massy-greene
peter gammell
the oneventures innovation fund
the oneventures innovation and growth fund
application for funding
here
series a and beyond
information for stakeholders interested in the significant investment visa (siv) programme
b
i
em
Bolds strong 19
b 0
i 0
em 0
Zawartość strony internetowej powinno zawierać więcej niż 250 słów, z stopa tekst / kod jest wyższy niż 20%.
Pozycji używać znaczników (h1, h2, h3, ...), aby określić temat sekcji lub ustępów na stronie, ale zwykle, użyj mniej niż 6 dla każdego tagu pozycje zachować swoją stronę zwięzły.
Styl używać silnych i kursywy znaczniki podkreślić swoje słowa kluczowe swojej stronie, ale nie nadużywać (mniej niż 16 silnych tagi i 16 znaczników kursywy)

Statystyki strony

twitter:title pusty
twitter:description pusty
google+ itemprop=name pusty
Pliki zewnętrzne 14
Pliki CSS 1
Pliki javascript 13
Plik należy zmniejszyć całkowite odwołanie plików (CSS + JavaScript) do 7-8 maksymalnie.

Linki wewnętrzne i zewnętrzne

Linki 93
Linki wewnętrzne 84
Linki zewnętrzne 9
Linki bez atrybutu Title 25
Linki z atrybutem NOFOLLOW 0
Linki - Użyj atrybutu tytuł dla każdego łącza. Nofollow link jest link, który nie pozwala wyszukiwarkom boty zrealizują są odnośniki no follow. Należy zwracać uwagę na ich użytkowania

Linki wewnętrzne

about us #aboutus
team #team
funds #funds
portfolio #portfolio
awards #awards
news #news
contact us #contactus
about us #aboutus
team #team
funds #funds
portfolio #portfolio
awards #awards
news #news
contact us #contactus
- /team/#mdeaker
- /team/#pkelly
- /team/#abirkill
- /team/#gwald
- /team/#azalcenstein
- /team/#jmcgrath
- /team/#hliu
- /team/#jjakob
- /team/
- /team/#wlewin
- /team/#smoore
- /team/#rmgreene
- /team/#pgammell
application for funding /contact-us/
here /contact-us/#contactus-siv
- /portfolio/#hatchtech
- /portfolio/#vaxxas
- /portfolio/#smartsparrow
- /portfolio/#palomamobile
- /portfolio/#buildingiq
- /portfolio/#incomingmedia
- /portfolio/#charmhealth
- /portfolio/#peak3
- /portfolio/#beasy
- /portfolio/#findme
- /portfolio/#clinicalgenomics
- /portfolio/#vaxxas-fundii
- /portfolio/#employmenthero
- /portfolio/#agamatrix
- /awards/
smart sparrow /portfolio/#smartsparrow
finalist in the bill and melinda gates foundation $20m digital courseware challenge /news-story/2014/10/02/smart-sparrow-wins-gates-e-learning-grant/
vaxxas /portfolio/#vaxxas
world economic forum technology pioneer 2015 /news-story/2014/08/28/vaxxas-selected-as-world-economic-forum-technology-pioneer-2015/
incoming media /portfolio/#incomingmedia
warner bros announces 2014 media camp class /news-story/2014/06/02/warner-bros.-entertainment-announces-2014-media-camp-class/
incoming media /portfolio/#incomingmedia
spiffy award nominee 2013 - ground breaking award for engineering /news-story/2013/07/24/2013-spiffy-award-nominees-announced---nominee-roster-catalogs-the-telecom-startup-watch-list/
smart sparrow /portfolio/#smartsparrow
vaxxas /portfolio/#vaxxas
see all awards /awards/
oneventures awarded biomedical translation $170m funding news-story/2016/12/14/oneventures-awarded-biomedical-translation-$170m-funding
pkelly@one-ventures.com mailto:pkelly@one-ventures.com
3 comments news-story/2016/12/14/oneventures-awarded-biomedical-translation-$170m-funding#comments
full story news-story/2016/12/14/oneventures-awarded-biomedical-translation-$170m-funding
oneventures awarded biomedical translation $170m funding news-story/2016/12/14/oneventures-awarded-biomedical-translation-$170m-funding
full story news-story/2016/12/14/oneventures-awarded-biomedical-translation-$170m-funding
data published in cancer medicine demostrate clinical genomics' blood test for colorectal cancer recurrence is two-fold more sensitive than cea test news-story/2016/10/19/data-published-in-cancer-medicine-demostrate-clinical-genomics'-blood-test-for-colorectal-cancer-recurrence-is-two-fold-more-sensitive-than-cea-test
full story news-story/2016/10/19/data-published-in-cancer-medicine-demostrate-clinical-genomics'-blood-test-for-colorectal-cancer-recurrence-is-two-fold-more-sensitive-than-cea-test
clinical genomics strenghtens it's leadership team with multiple key appointments news-story/2016/10/19/clinical-genomics-strenghtens-it's-leadership-team-with-multiple-key-appointments
full story news-story/2016/10/19/clinical-genomics-strenghtens-it's-leadership-team-with-multiple-key-appointments
media release - oneventures appoints dr graeme wald to life sciences investment team news-story/2016/09/01/media-release---oneventures-appoints-dr-graeme-wald-to-life-sciences-investment-team
full story news-story/2016/09/01/media-release---oneventures-appoints-dr-graeme-wald-to-life-sciences-investment-team
dror ben-naim puts digital power in professor's hands news-story/2016/07/22/dror-ben-naim-puts-digital-power-in-professor's-hands
full story news-story/2016/07/22/dror-ben-naim-puts-digital-power-in-professor's-hands
see all news /news/
entrepreneurs@one-ventures.com mailto:entrepreneurs@one-ventures.com
back to the top #pagetop
disclaimer /disclaimer/
contact us /contact-us/

Linki zewnętrzne

- http://sb.co/programs/australia/
- http://headsoverheels.com.au/
- http://www.ilabaccelerator.com/
- https://investor.one-ventures.com/default.aspx
- http://linkedin.com/groups/oneventures-4458377?goback=.gan_4458377
global impact learning awards 2013 (silver) http://www.one-ventures.com.au/news-story/2013/07/18/smart-sparrow-wins-silver-at-learning-impact-2013-san-diego/
biospectrum emerging company of the year 2012 http://www.vaxxas.com/news/vaxxas-recognised-as-2013-biospectrum-asia-pacific-emerging-company-of-the-year/
austrade website http://www.austrade.gov.au/invest/significant-investor-visa-and-premium-investor-visa-programmes/
here http://www.avcal.com.au/avcalnews/new-significant-investor-visa-regulations-issued/

Zdjęcia

Zdjęcia 34
Zdjęcia bez atrybutu ALT 0
Zdjęcia bez atrybutu TITLE 7
Korzystanie Obraz ALT i TITLE atrybutu dla każdego obrazu.

Zdjęcia bez atrybutu TITLE

/images/default-source/oneventures_2.0/springboard_logo_120x56.jpg?sfvrsn=0
/images/default-source/oneventures_2.0/heads-over-heels_logo_90x56.jpg?sfvrsn=0
/images/default-source/oneventures_2.0/ilab_logo_80x56.jpg?sfvrsn=0
/images/portfolio-images/linkedin-monochrome.jpg?sfvrsn=0
/images/default-source/oneventures_2.0/team_wlewin_201609_203x237.jpg?sfvrsn=0
/images/default-source/oneventures_2.0/team_rmgreene_201609_203x237.jpg?sfvrsn=0
/images/default-source/oneventures_2.0/team_pgammell_201609_203x237.jpg?sfvrsn=0

Zdjęcia bez atrybutu ALT

empty

Ranking:


Alexa Traffic
Daily Global Rank Trend
Daily Reach (Percent)









Majestic SEO











Text on page:

about us team funds portfolio awards news contact us about us team funds portfolio awards news contact us oneventures is a venture capital firm headquartered in sydney, australia that provides human and investment capital into high growth companies with a particular focus on transformative technologies. the firm is particularly focused on opportunities originating in australia which are poised to expand into the established and emerging global markets. all of our partners have founded, built and exited high-growth businesses. our goal is to be the leading australian venture capital company. proudly supporting connect with us about oneventures oneventures invests in technology companies that serve or disrupt large high growth global markets. the firm has $170m in funds under management recently launching its new innovation and growth fund ii which is focused on growth and expansion stage technology companies. oneventures is managed by a team of partners with a skill-set and track record ideally suited to collaboration with entrepreneurial management teams to foster growth and create value: a unique blend of highly successful entrepreneurs, technology business founders and corporate executives with a strong scientific pedigree, extensive off-shore experience and networks. the oneventures team is committed to deliver investor returns by applying this expertise to select portfolio companies with significant potential then accelerating their performance. afsl oneventures management pty ltd is a designate under oneventures nominees pty ltd's afsl (licence no: 462825) issued by the australian securities and investments commissions, authorising the manager to provide such financial services as the manager provides during the course of its duties as manager of the fund. the oneventures team all partners have many years of c-level, board and investment experience. coupled with this is a track record of identifying investment opportunities in global markets with strong international business backgrounds and networks. the oneventures investment team has 7 technology related higher degrees. dr michelle deaker managing director and ceo dr paul kelly partner and managing director anne-marie birkill general partner and executive director graeme wald venture partner dr amir zalcenstein investment manager, healthcare james mcgrath investment analyst helen liu chief financial officer jelly jakob accounts jen ball office manager member name title board of directors walter lewin oneventures board of directors simon moore oneventures board of directors roger massy-greene oneventures board of directors peter gammell oneventures board of directors funds innovation fund (fund i) the oneventures innovation fund is a $40m venture capital fund formed as an early stage venture capital limited partnership. this fund was launched in 2010 with the commonwealth government committing $20m from its iif programme and this funding matched by high net-worth wholesale investors. innovation and growth fund (fund ii) the oneventures innovation and growth fund was launched in march 2014 with a target of $100m and reached that target in december 2015. fund ii is an early stage venture capital limited partnership backed entirely by australian high net-worth wholesale investors. focusing on later stage (series b and beyond) investments while still maintaining some investment activity in the earlier stage investments, fund ii is now screening investment opportunities where the experience of the oneventures management team can be leveraged to accelerate value creation and company success. we are currently looking for truly transformative companies to join our portfolio of innovative companies, if you think your company has what it takes, read our application for funding page and submit your application now. information for stakeholders interested in the significant investment visa (siv) programme information for stakeholders interested in the significant investment visa programme can be found here. investment portfolio oneventures innovation fund (fund i) oneventures innovation and growth fund (fund ii) other investments awards and accolades oneventures innovation fund (fund i) other investments smart sparrow september 30, 2014 finalist in the bill and melinda gates foundation $20m digital courseware challenge vaxxas august 26, 2014 world economic forum technology pioneer 2015 incoming media may 29, 2014 warner bros announces 2014 media camp class incoming media july 15, 2013 spiffy award nominee 2013 - ground breaking award for engineering smart sparrow may 2, 2013 global impact learning awards 2013 (silver) vaxxas march 18, 2013 biospectrum emerging company of the year 2012 see all awards latest news oneventures awarded biomedical translation $170m funding by we buchan | dec 14, 2016 oneventures, a venture capital firm focused on investment in high growth, transformative technology and life sciences companies, is pleased to announce it has been selected as an investment manager for the biomedical translation fund (btf), and is launching the oneventures healthcare fund iii in january 2017. oneventures has been granted funding of $85 million, matching the funds it has raised with its investment partners and establishing the $170 million oneventures healthcare fund iii to invest in privately owned, clinical stage drug development and medical technologies. the investment mandate is in line with the guidelines of the btf which was established by the australian government to provide a pool of public and private funds for investment in promising biomedical innovations with commercialisation potential. “oneventures has a track record of helping commercialise the outputs of promising australian research and innovation, by providing the funding and human capital to make this transition. the launch of this new fund effectively doubles our capacity to invest in great australian biomedical innovation and convert those discoveries into commercial products for the global health market,” said dr paul kelly, managing partner of oneventures, and head of healthcare and lifesciences at oneventures. “we are absolutely delighted to have been selected as one of the investment managers for the biomedical translation fund. we congratulate the government on supporting investors and australian companies alike by establishing the btf which has been specifically designed to help companies traverse the ‘second valley of death’, providing funding for later stage developments which have achieved proof of concept, but – until now – have had few options to fund the clinical and commercial development required to advance to market.” the oneventures healthcare fund iii will be open for business in january 2017, and will be looking to make initial investments in the first half of 2017, investing $10 to $20 million in each individual company. the fund will invest companies commercialising medical devices, drugs in clinical development or diagnostics. the fund’s investment criteria requires that investee companies have reached clinical proof of concept, with phase 1 or equivalent trial results; have a clear commercial, regulatory and reimbursement pathway; and clear value inflection and exit points on deal entry. the fund has a three to five year investment horizon. for more information, contact: paul kelly tel: +61 2 8205 7379 email: pkelly@one-ventures.com 3 comments full story oneventures awarded biomedical translation $170m funding dec 14, 2016 full story data published in cancer medicine demostrate clinical genomics' blood test for colorectal cancer recurrence is two-fold more sensitive than cea test oct 19, 2016 full story clinical genomics strenghtens it's leadership team with multiple key appointments oct 19, 2016 full story media release - oneventures appoints dr graeme wald to life sciences investment team sep 01, 2016 full story dror ben-naim puts digital power in professor's hands jul 22, 2016 full story see all news contact us for entrepreneurs we are now screening companies for oneventures fund ii which is a series a and beyond growth fund focusing on the technology sector. to qualify for funding, your company should meet the following criteria: australian domiciled company we invest in technology companies from many sectors, but we are particularly interested in companies from the following sectors: healthcare, education, mobile, media, cloud computing and data, security and privacy, machine learning, software, sensors and robotics or food security if a life sciences company, your product should have a strong proof of concept and be at a minimum, in a late stage clinical trial and/or well progressed through the regulatory process if from another sector, your company should be generating sustainable revenue and have a strong market validation approaching profitability with capital required to fuel growth and global expansion if you meet the above criteria, send us a brief document (a 2-page executive summary or introductory powerpoint is sufficient, please do not send larger documents or full information memorandums at this stage) covering at a minimum the following points to entrepreneurs@one-ventures.com: summarize in 2 sentences what your company does (this is important) identify the market, value proposition and your competitive advantage tell us about your progress to date state your revenue for the last financial year and projected revenue for current financial year indicate capital required and how it will be used include 3 point bios of each executive and contact details we will review your proposal and endeavour to revert to you within 2 weeks. for investors investor enquiries: investors@one-ventures.com information for stakeholders interested in the significant investment visa (siv) programme the significant investor visa (siv) programme was revised with the announcement in may 2015 of a new complying investment framework. the new framework mandated that siv applicants would be required to invest a minimum of $500,000 at the at time of investment in an ausindustry registered fund(s): that is, a vclp, esvclp or an australian vc fund-of-fund as registered under the venture capital act 2002. the minimum amount is expected to be increased within two years as the market responds. the austrade website has more information regarding the programme available, including information sheets in english and chinese. the relevant regulations can be accessed here. oneventures is not at this time accepting new capital commitments and is therefore not in a position to receive funding from individual siv applicants. when this situation changes we will provide details here and on the avcal website. we are however receiving proposals from siv fund of funds interested in becoming a oneventures siv partner for 2016 and beyond. if you represent a fund of funds and meet the following criteria we request you submit a brief proposal for our consideration. our criteria: you should have a track record in servicing siv applicants you should have an established australian aml/ctf kyc compliance framework that oneventures can rely on in accepting siv funding you should be an ausindustry compliant fund of funds structure – oneventures will not accept direct investment from individual siv applicants at this stage you should have a fund of funds structure that can invest the capital for up to 10 years in line with our funding cycle your proposal should address those key criteria and provide information about: the directors the management team your track record in providing siv applicants with a return on investment how you will ensure aml/ctf kyc compliance including details of any external providers that support this process details of any relevant reporting and financial operational requirements we should consider your ability to source capital and the % of siv market you currently hold/expected quantum of capital you would be looking to deploy p.a. to vc we plan to work with up to 3 such partners only and will determine the parties with whom we wish to progress discussions by december 2015. general enquiries back to the top general enquiries: admin@one-ventures.com telephone: +61 2 8205 7379facsimile: +61 2 9247 9181 //--> sydney oneventures pty ltd level 13 179 elizabeth street sydney nsw 2000 australia brisbane c/- interfinancial level 3, tc beirne building 315 brunswick street fortitude valley qld 4006 australia © 2015 oneventures pty ltd one vision, one team, one purpose disclaimer|contact us


Here you find all texts from your page as Google (googlebot) and others search engines seen it.

Words density analysis:

Numbers of all words: 1887

One word

Two words phrases

Three words phrases

the - 4.13% (78)
and - 3.6% (68)
fund - 3.07% (58)
venture - 2.6% (49)
invest - 2.54% (48)
one - 2.49% (47)
for - 2.07% (39)
oneventures - 1.96% (37)
investment - 1.64% (31)
our - 1.32% (25)
you - 1.32% (25)
with - 1.22% (23)
can - 0.9% (17)
capital - 0.79% (15)
any - 0.74% (14)
are - 0.74% (14)
companies - 0.74% (14)
australia - 0.74% (14)
your - 0.69% (13)
siv - 0.69% (13)
partner - 0.64% (12)
have - 0.64% (12)
team - 0.64% (12)
this - 0.64% (12)
growth - 0.64% (12)
funding - 0.58% (11)
innovation - 0.58% (11)
has - 0.58% (11)
all - 0.53% (10)
stage - 0.53% (10)
funds - 0.53% (10)
company - 0.53% (10)
direct - 0.53% (10)
australian - 0.53% (10)
new - 0.48% (9)
director - 0.48% (9)
market - 0.48% (9)
act - 0.48% (9)
that - 0.48% (9)
will - 0.48% (9)
award - 0.48% (9)
should - 0.48% (9)
high - 0.42% (8)
information - 0.42% (8)
technology - 0.42% (8)
investor - 0.42% (8)
medical - 0.42% (8)
2016 - 0.37% (7)
year - 0.37% (7)
manager - 0.37% (7)
clinical - 0.37% (7)
health - 0.37% (7)
from - 0.37% (7)
partners - 0.37% (7)
full - 0.37% (7)
provide - 0.37% (7)
directors - 0.32% (6)
board - 0.32% (6)
investments - 0.32% (6)
programme - 0.32% (6)
financial - 0.32% (6)
healthcare - 0.32% (6)
late - 0.32% (6)
focus - 0.32% (6)
work - 0.32% (6)
biomedical - 0.32% (6)
contact - 0.32% (6)
commercial - 0.32% (6)
global - 0.32% (6)
criteria - 0.32% (6)
which - 0.32% (6)
story - 0.32% (6)
point - 0.32% (6)
(fund - 0.26% (5)
here - 0.26% (5)
applicants - 0.26% (5)
2015 - 0.26% (5)
2014 - 0.26% (5)
not - 0.26% (5)
media - 0.26% (5)
investors - 0.26% (5)
launch - 0.26% (5)
interested - 0.26% (5)
about - 0.26% (5)
2013 - 0.26% (5)
track - 0.26% (5)
significant - 0.26% (5)
management - 0.26% (5)
portfolio - 0.26% (5)
record - 0.26% (5)
awards - 0.26% (5)
kelly - 0.21% (4)
two - 0.21% (4)
pty - 0.21% (4)
visa - 0.21% (4)
found - 0.21% (4)
proposal - 0.21% (4)
details - 0.21% (4)
strong - 0.21% (4)
business - 0.21% (4)
dec - 0.21% (4)
translation - 0.21% (4)
value - 0.21% (4)
life - 0.21% (4)
sciences - 0.21% (4)
been - 0.21% (4)
minimum - 0.21% (4)
$170 - 0.21% (4)
its - 0.21% (4)
development - 0.21% (4)
under - 0.21% (4)
following - 0.21% (4)
required - 0.21% (4)
each - 0.21% (4)
ltd - 0.21% (4)
used - 0.21% (4)
now - 0.21% (4)
was - 0.21% (4)
news - 0.21% (4)
firm - 0.21% (4)
executive - 0.21% (4)
million - 0.16% (3)
btf - 0.16% (3)
line - 0.16% (3)
sydney - 0.16% (3)
managing - 0.16% (3)
markets - 0.16% (3)
enquiries - 0.16% (3)
back - 0.16% (3)
transformative - 0.16% (3)
providing - 0.16% (3)
announce - 0.16% (3)
government - 0.16% (3)
progress - 0.16% (3)
revenue - 0.16% (3)
$170m - 0.16% (3)
paul - 0.16% (3)
entrepreneurs - 0.16% (3)
established - 0.16% (3)
+61 - 0.16% (3)
more - 0.16% (3)
points - 0.16% (3)
individual - 0.16% (3)
$20 - 0.16% (3)
beyond - 0.16% (3)
support - 0.16% (3)
- 0.16% (3)
focused - 0.16% (3)
meet - 0.16% (3)
proof - 0.16% (3)
level - 0.16% (3)
general - 0.16% (3)
concept - 0.16% (3)
years - 0.16% (3)
iii - 0.16% (3)
date - 0.16% (3)
may - 0.16% (3)
looking - 0.16% (3)
stakeholders - 0.16% (3)
select - 0.16% (3)
into - 0.16% (3)
other - 0.16% (3)
framework - 0.16% (3)
experience - 0.16% (3)
(siv) - 0.16% (3)
accept - 0.16% (3)
how - 0.16% (3)
current - 0.16% (3)
opportunities - 0.16% (3)
test - 0.16% (3)
particular - 0.16% (3)
power - 0.11% (2)
time - 0.11% (2)
street - 0.11% (2)
ausindustry - 0.11% (2)
series - 0.11% (2)
registered - 0.11% (2)
provides - 0.11% (2)
expected - 0.11% (2)
jul - 0.11% (2)
puts - 0.11% (2)
human - 0.11% (2)
sep - 0.11% (2)
key - 0.11% (2)
position - 0.11% (2)
genomics - 0.11% (2)
accepting - 0.11% (2)
relevant - 0.11% (2)
19, - 0.11% (2)
oct - 0.11% (2)
website - 0.11% (2)
would - 0.11% (2)
aml/ctf - 0.11% (2)
bios - 0.11% (2)
ability - 0.11% (2)
structure - 0.11% (2)
document - 0.11% (2)
brief - 0.11% (2)
rely - 0.11% (2)
within - 0.11% (2)
send - 0.11% (2)
enquiries: - 0.11% (2)
please - 0.11% (2)
technologies. - 0.11% (2)
identify - 0.11% (2)
return - 0.11% (2)
process - 0.11% (2)
compliance - 0.11% (2)
particularly - 0.11% (2)
consider - 0.11% (2)
kyc - 0.11% (2)
product - 0.11% (2)
security - 0.11% (2)
criteria: - 0.11% (2)
including - 0.11% (2)
market, - 0.11% (2)
help - 0.11% (2)
cancer - 0.11% (2)
afsl - 0.11% (2)
focusing - 0.11% (2)
later - 0.11% (2)
screening - 0.11% (2)
such - 0.11% (2)
currently - 0.11% (2)
companies, - 0.11% (2)
potential - 0.11% (2)
2015. - 0.11% (2)
what - 0.11% (2)
application - 0.11% (2)
page - 0.11% (2)
submit - 0.11% (2)
here. - 0.11% (2)
smart - 0.11% (2)
sparrow - 0.11% (2)
partnership - 0.11% (2)
december - 0.11% (2)
vaxxas - 0.11% (2)
many - 0.11% (2)
graeme - 0.11% (2)
wald - 0.11% (2)
office - 0.11% (2)
early - 0.11% (2)
limited - 0.11% (2)
launched - 0.11% (2)
$20m - 0.11% (2)
fund. - 0.11% (2)
reached - 0.11% (2)
net-worth - 0.11% (2)
wholesale - 0.11% (2)
investors. - 0.11% (2)
ii) - 0.11% (2)
march - 0.11% (2)
course - 0.11% (2)
target - 0.11% (2)
digital - 0.11% (2)
networks. - 0.11% (2)
data - 0.11% (2)
$10 - 0.11% (2)
supporting - 0.11% (2)
company. - 0.11% (2)
valley - 0.11% (2)
concept, - 0.11% (2)
but - 0.11% (2)
markets. - 0.11% (2)
2017, - 0.11% (2)
emerging - 0.11% (2)
large - 0.11% (2)
trial - 0.11% (2)
clear - 0.11% (2)
regulatory - 0.11% (2)
exit - 0.11% (2)
deal - 0.11% (2)
8205 - 0.11% (2)
7379 - 0.11% (2)
head - 0.11% (2)
those - 0.11% (2)
incoming - 0.11% (2)
oneventures, - 0.11% (2)
nominee - 0.11% (2)
ground - 0.11% (2)
learning - 0.11% (2)
see - 0.11% (2)
awarded - 0.11% (2)
14, - 0.11% (2)
expansion - 0.11% (2)
selected - 0.11% (2)
make - 0.11% (2)
january - 0.11% (2)
establishing - 0.11% (2)
launching - 0.11% (2)
drug - 0.11% (2)
mandate - 0.11% (2)
private - 0.11% (2)
promising - 0.11% (2)
nsw - 0.11% (2)
fund ii - 0.48% (9)
the oneventures - 0.42% (8)
venture capital - 0.37% (7)
have a - 0.37% (7)
full story - 0.32% (6)
the fund - 0.32% (6)
in the - 0.32% (6)
we are - 0.26% (5)
of the - 0.26% (5)
of directors - 0.26% (5)
growth fund - 0.26% (5)
innovation and - 0.26% (5)
fund (fund - 0.26% (5)
oneventures innovation - 0.26% (5)
with a - 0.26% (5)
siv applicants - 0.26% (5)
track record - 0.26% (5)
interested in - 0.26% (5)
2016 full - 0.26% (5)
your company - 0.21% (4)
biomedical translation - 0.21% (4)
and be - 0.21% (4)
oneventures board - 0.21% (4)
innovation fund - 0.21% (4)
the significant - 0.21% (4)
and growth - 0.21% (4)
for the - 0.21% (4)
should have - 0.21% (4)
of funds - 0.21% (4)
contact us - 0.21% (4)
fund of - 0.21% (4)
you should - 0.21% (4)
healthcare fund - 0.16% (3)
invest in - 0.16% (3)
meet the - 0.16% (3)
and beyond - 0.16% (3)
has been - 0.16% (3)
if you - 0.16% (3)
to invest - 0.16% (3)
technology companies - 0.16% (3)
(fund i) - 0.16% (3)
information for - 0.16% (3)
stakeholders interested - 0.16% (3)
us about - 0.16% (3)
significant investment - 0.16% (3)
visa (siv) - 0.16% (3)
for stakeholders - 0.16% (3)
news contact - 0.16% (3)
oneventures is - 0.16% (3)
investment visa - 0.16% (3)
life sciences - 0.16% (3)
will be - 0.16% (3)
required to - 0.16% (3)
a track - 0.16% (3)
investment manager - 0.16% (3)
global markets - 0.16% (3)
investment in - 0.16% (3)
focused on - 0.16% (3)
at this - 0.16% (3)
growth and - 0.16% (3)
proof of - 0.16% (3)
high growth - 0.16% (3)
oneventures healthcare - 0.16% (3)
with the - 0.16% (3)
of concept - 0.16% (3)
fund iii - 0.16% (3)
the biomedical - 0.11% (2)
of concept, - 0.11% (2)
8205 7379 - 0.11% (2)
looking to - 0.11% (2)
selected as - 0.11% (2)
btf which - 0.11% (2)
about us - 0.11% (2)
oct 19, - 0.11% (2)
individual siv - 0.11% (2)
general enquiries - 0.11% (2)
details of - 0.11% (2)
of any - 0.11% (2)
kyc compliance - 0.11% (2)
line with - 0.11% (2)
a fund - 0.11% (2)
from individual - 0.11% (2)
aml/ctf kyc - 0.11% (2)
following criteria - 0.11% (2)
the market - 0.11% (2)
19, 2016 - 0.11% (2)
an ausindustry - 0.11% (2)
would be - 0.11% (2)
your proposal - 0.11% (2)
financial year - 0.11% (2)
a brief - 0.11% (2)
capital required - 0.11% (2)
should be - 0.11% (2)
company should - 0.11% (2)
now screening - 0.11% (2)
to make - 0.11% (2)
oneventures awarded - 0.11% (2)
the australian - 0.11% (2)
and networks. - 0.11% (2)
graeme wald - 0.11% (2)
partner and - 0.11% (2)
dr paul - 0.11% (2)
managing director - 0.11% (2)
networks. the - 0.11% (2)
record of - 0.11% (2)
this is - 0.11% (2)
to provide - 0.11% (2)
the manager - 0.11% (2)
by the - 0.11% (2)
companies with - 0.11% (2)
ii which - 0.11% (2)
early stage - 0.11% (2)
the firm - 0.11% (2)
global markets. - 0.11% (2)
in technology - 0.11% (2)
partners have - 0.11% (2)
technologies. the - 0.11% (2)
capital firm - 0.11% (2)
a venture - 0.11% (2)
awards news - 0.11% (2)
funds portfolio - 0.11% (2)
us team - 0.11% (2)
portfolio awards - 0.11% (2)
i) the - 0.11% (2)
this fund - 0.11% (2)
the btf - 0.11% (2)
incoming media - 0.11% (2)
in line - 0.11% (2)
the investment - 0.11% (2)
establishing the - 0.11% (2)
in january - 0.11% (2)
and is - 0.11% (2)
been selected - 0.11% (2)
it has - 0.11% (2)
and life - 0.11% (2)
dec 14, - 0.11% (2)
$170m funding - 0.11% (2)
team funds - 0.11% (2)
i) other - 0.11% (2)
was launched - 0.11% (2)
for funding - 0.11% (2)
our application - 0.11% (2)
oneventures management - 0.11% (2)
later stage - 0.11% (2)
focusing on - 0.11% (2)
wholesale investors. - 0.11% (2)
high net-worth - 0.11% (2)
limited partnership - 0.11% (2)
december 2015. - 0.11% (2)
launched in - 0.11% (2)
fund was - 0.11% (2)
net-worth wholesale - 0.11% (2)
oneventures pty - 0.11% (2)
2016 full story - 0.26% (5)
innovation and growth - 0.21% (4)
oneventures board of - 0.21% (4)
fund of funds - 0.21% (4)
should have a - 0.21% (4)
and growth fund - 0.21% (4)
innovation fund (fund - 0.16% (3)
you should have - 0.16% (3)
information for stakeholders - 0.16% (3)
fund (fund i) - 0.16% (3)
oneventures innovation fund - 0.16% (3)
in the significant - 0.16% (3)
for stakeholders interested - 0.16% (3)
news contact us - 0.16% (3)
significant investment visa - 0.16% (3)
interested in the - 0.16% (3)
the btf which - 0.11% (2)
the biomedical translation - 0.11% (2)
in line with - 0.11% (2)
fund ii which - 0.11% (2)
proof of concept, - 0.11% (2)
be looking to - 0.11% (2)
awarded biomedical translation - 0.11% (2)
for the biomedical - 0.11% (2)
your company should - 0.11% (2)
investment visa (siv) - 0.11% (2)
track record in - 0.11% (2)
aml/ctf kyc compliance - 0.11% (2)
from individual siv - 0.11% (2)
of funds structure - 0.11% (2)
the oneventures healthcare - 0.11% (2)
about us team - 0.11% (2)
been selected as - 0.11% (2)
venture capital limited - 0.11% (2)
venture capital firm - 0.11% (2)
ii which is - 0.11% (2)
and networks. the - 0.11% (2)
track record of - 0.11% (2)
networks. the oneventures - 0.11% (2)
dr paul kelly - 0.11% (2)
the oneventures innovation - 0.11% (2)
an early stage - 0.11% (2)
was launched in - 0.11% (2)
translation $170m funding - 0.11% (2)
oneventures innovation and - 0.11% (2)
stage venture capital - 0.11% (2)
high net-worth wholesale - 0.11% (2)
fund ii is - 0.11% (2)
funds portfolio awards - 0.11% (2)
fund (fund ii) - 0.11% (2)
i) other investments - 0.11% (2)
oneventures awarded biomedical - 0.11% (2)
+61 2 8205 - 0.11% (2)

Here you can find chart of all your popular one, two and three word phrases. Google and others search engines means your page is about words you use frequently.

Copyright © 2015-2016 hupso.pl. All rights reserved. FB | +G | Twitter

Hupso.pl jest serwisem internetowym, w którym jednym kliknieciem możesz szybko i łatwo sprawdź stronę www pod kątem SEO. Oferujemy darmowe pozycjonowanie stron internetowych oraz wycena domen i stron internetowych. Prowadzimy ranking polskich stron internetowych oraz ranking stron alexa.